异动解读 | 福泰制药新型止痛药临床试验失败，夜盘股价大跌15.07%

异动解读

Aug 05

福泰制药（Vertex Pharmaceuticals，股票代码：VRTX）在夜盘交易中股价大跌15.07%，引发市场广泛关注。这一大幅下跌主要源于公司公布的一则重磅消息。

据悉，福泰制药备受关注的实验性非阿片类止痛药VX-993在中期临床试验中未能达到主要目标。公司表示，该药物在48小时内能使疼痛减轻74.5点，而安慰剂组的疼痛减轻幅度为50.2点，但两组之间的差异没有统计学意义。基于这一结果，福泰制药宣布将不再继续将VX-993作为单独治疗方案进行开发。

这一消息对福泰制药在疼痛管理领域的扩张计划造成了重大打击。VX-993原本被视为公司在非阿片类止痛药市场中的重要布局，其失败不仅影响了公司在该领域的战略地位，也引发了投资者对公司未来增长前景的担忧。分析人士指出，这次临床试验的失败可能会迫使公司重新评估其在疼痛管理领域的研发策略。

尽管新药研发遭遇挫折，福泰制药在财务表现方面仍然保持稳健。公司最新公布的第二季度营收为29.6亿美元，超过了分析师预期的29.1亿美元。然而，这些积极的财务数据似乎未能抵消投资者对新药研发失利的失望情绪。市场将密切关注福泰制药未来在疼痛管理领域的战略调整和其他管线产品的进展。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1160374699"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1160374699\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1160374699?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-08-05 15:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1160374699","market":"nz","top_or_hot":-1,"title":"异动解读 | 福泰制药新型止痛药临床试验失败，夜盘股价大跌15.07%","media":"异动解读","content":"<p>福泰制药（Vertex Pharmaceuticals，股票代码：VRTX）在夜盘交易中股价大跌15.07%，引发市场广泛关注。这一大幅下跌主要源于公司公布的一则重磅消息。</p>\n\n<p>据悉，福泰制药备受关注的实验性非阿片类止痛药VX-993在中期临床试验中未能达到主要目标。公司表示，该药物在48小时内能使疼痛减轻74.5点，而安慰剂组的疼痛减轻幅度为50.2点，但两组之间的差异没有统计学意义。基于这一结果，福泰制药宣布将不再继续将VX-993作为单独治疗方案进行开发。</p>\n\n<p>这一消息对福泰制药在疼痛管理领域的扩张计划造成了重大打击。VX-993原本被视为公司在非阿片类止痛药市场中的重要布局，其失败不仅影响了公司在该领域的战略地位，也引发了投资者对公司未来增长前景的担忧。分析人士指出，这次临床试验的失败可能会迫使公司重新评估其在疼痛管理领域的研发策略。</p>\n\n<p>尽管新药研发遭遇挫折，福泰制药在财务表现方面仍然保持稳健。公司最新公布的第二季度营收为29.6亿美元，超过了分析师预期的29.1亿美元。然而，这些积极的财务数据似乎未能抵消投资者对新药研发失利的失望情绪。市场将密切关注福泰制药未来在疼痛管理领域的战略调整和其他管线产品的进展。</p>","source":"ai_movement_cn","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>异动解读 | 福泰制药新型止痛药临床试验失败，夜盘股价大跌15.07%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n异动解读 | 福泰制药新型止痛药临床试验失败，夜盘股价大跌15.07%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092702339\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">异动解读 </p>\n<p class=\"h-time\">2025-08-05 15:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>福泰制药（Vertex Pharmaceuticals，股票代码：VRTX）在夜盘交易中股价大跌15.07%，引发市场广泛关注。这一大幅下跌主要源于公司公布的一则重磅消息。</p>\n\n<p>据悉，福泰制药备受关注的实验性非阿片类止痛药VX-993在中期临床试验中未能达到主要目标。公司表示，该药物在48小时内能使疼痛减轻74.5点，而安慰剂组的疼痛减轻幅度为50.2点，但两组之间的差异没有统计学意义。基于这一结果，福泰制药宣布将不再继续将VX-993作为单独治疗方案进行开发。</p>\n\n<p>这一消息对福泰制药在疼痛管理领域的扩张计划造成了重大打击。VX-993原本被视为公司在非阿片类止痛药市场中的重要布局，其失败不仅影响了公司在该领域的战略地位，也引发了投资者对公司未来增长前景的担忧。分析人士指出，这次临床试验的失败可能会迫使公司重新评估其在疼痛管理领域的研发策略。</p>\n\n<p>尽管新药研发遭遇挫折，福泰制药在财务表现方面仍然保持稳健。公司最新公布的第二季度营收为29.6亿美元，超过了分析师预期的29.1亿美元。然而，这些积极的财务数据似乎未能抵消投资者对新药研发失利的失望情绪。市场将密切关注福泰制药未来在疼痛管理领域的战略调整和其他管线产品的进展。</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VRTX","symbol_name":"福泰制药","start_time":0,"source_url":"","article_id":"1160374699","we_media_id":"1092702339","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1160374699","pubTimestamp":1754378563,"columns":[],"sourceInfo":{"source_id":"ai_movement_cn","name":"异动解读"},"weMediaInfo":{"media_name":"异动解读","introduction":"个股异动一手消息解读","home_visible":1,"id":"1092702339","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"福泰制药在夜盘交易中股价大跌15.07%，引发市场广泛关注。这一大幅下跌主要源于公司公布的一则重磅消息。据悉，福泰制药备受关注的实验性非阿片类止痛药VX-993在中期临床试验中未能达到主要目标。基于这一结果，福泰制药宣布将不再继续将VX-993作为单独治疗方案进行开发。这一消息对福泰制药在疼痛管理领域的扩张计划造成了重大打击。尽管新药研发遭遇挫折，福泰制药在财务表现方面仍然保持稳健。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"VRTX":"福泰制药"},"translate_title":"Interpretation of changes | Futai Pharmaceutical's new painkiller clinical trial failed, and its stock price fell 15.07% in night trading","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VRTX":1},"content_text":"福泰制药（Vertex Pharmaceuticals，股票代码：VRTX）在夜盘交易中股价大跌15.07%，引发市场广泛关注。这一大幅下跌主要源于公司公布的一则重磅消息。\n据悉，福泰制药备受关注的实验性非阿片类止痛药VX-993在中期临床试验中未能达到主要目标。公司表示，该药物在48小时内能使疼痛减轻74.5点，而安慰剂组的疼痛减轻幅度为50.2点，但两组之间的差异没有统计学意义。基于这一结果，福泰制药宣布将不再继续将VX-993作为单独治疗方案进行开发。\n这一消息对福泰制药在疼痛管理领域的扩张计划造成了重大打击。VX-993原本被视为公司在非阿片类止痛药市场中的重要布局，其失败不仅影响了公司在该领域的战略地位，也引发了投资者对公司未来增长前景的担忧。分析人士指出，这次临床试验的失败可能会迫使公司重新评估其在疼痛管理领域的研发策略。\n尽管新药研发遭遇挫折，福泰制药在财务表现方面仍然保持稳健。公司最新公布的第二季度营收为29.6亿美元，超过了分析师预期的29.1亿美元。然而，这些积极的财务数据似乎未能抵消投资者对新药研发失利的失望情绪。市场将密切关注福泰制药未来在疼痛管理领域的战略调整和其他管线产品的进展。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}